search
Back to results

Insulin Clamp Ancillary Study for Assessment of Insulin Resistance

Primary Purpose

Type 1 Diabetes

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Metformin
Placebo
Sponsored by
Jaeb Center for Health Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes

Eligibility Criteria

12 Years - 19 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

1. Meets eligibility criteria of the main study, Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (NCT01881828).

Exclusion Criteria:

1. Low hemoglobin or hematocrit as defined by each local institution's rules for insulin clamps or if no institutional requirements a Hematocrit <30% or hemoglobin <10 gm/dL

Sites / Locations

  • Jaeb Center for Health Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Oral Placebo

Metformin

Arm Description

A central pharmacy will compound a placebo to match the metformin tablets. The placebo product will contain the following components: Micosolle™, silica based excipient Silicified Micro Crystalline Cellulose, National Formulary Safflower Oil, United States Pharmacopeia K-30 Povidone Powder Magnesium Stearate, National Formulary (Vegetable source) Fumed Silica, National Formulary

Metformin 2000 mg per day

Outcomes

Primary Outcome Measures

Change in insulin resistance (IR) from baseline to 13 weeks
Hyperinsulinemic euglycemic clamp to assess metformin's impact on muscle IR via glucose infusion rate (GIR).

Secondary Outcome Measures

Change in Hepatic IR from baseline to 13 weeks
Graded hyperinsulinemic euglycemic clamp with glucose and glycerol isotopes to assess metformin's impact on: • Hepatic IR
Change in Adipose IR from baseline to 13 weeks
Graded hyperinsulinemic euglycemic clamp with glucose and glycerol isotopes to assess metformin's impact on: • Adipose IR

Full Information

First Posted
January 15, 2014
Last Updated
March 10, 2017
Sponsor
Jaeb Center for Health Research
Collaborators
Juvenile Diabetes Research Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT02045290
Brief Title
Insulin Clamp Ancillary Study for Assessment of Insulin Resistance
Official Title
Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
February 15, 2016 (Actual)
Study Completion Date
February 15, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jaeb Center for Health Research
Collaborators
Juvenile Diabetes Research Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Insulin Clamp Ancillary study for Assessment of Insulin Resistance will be conducted as a sub-study to the main protocol, Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (NCT01881828). The purpose of this ancillary study is to assess if metformin will improve tissue-specific insulin resistance (IR) in type 1 diabetes using a hyperinsulinemic euglycemic clamp; a 3-month randomized trial comparing metformin versus placebo in 12 to <20 year olds with BMI >85th percentile ( total daily insulin dose >0.7 units/kg, and HbA1c 7.0%-9.9%).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
37 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oral Placebo
Arm Type
Placebo Comparator
Arm Description
A central pharmacy will compound a placebo to match the metformin tablets. The placebo product will contain the following components: Micosolle™, silica based excipient Silicified Micro Crystalline Cellulose, National Formulary Safflower Oil, United States Pharmacopeia K-30 Povidone Powder Magnesium Stearate, National Formulary (Vegetable source) Fumed Silica, National Formulary
Arm Title
Metformin
Arm Type
Experimental
Arm Description
Metformin 2000 mg per day
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change in insulin resistance (IR) from baseline to 13 weeks
Description
Hyperinsulinemic euglycemic clamp to assess metformin's impact on muscle IR via glucose infusion rate (GIR).
Time Frame
0-13 weeks
Secondary Outcome Measure Information:
Title
Change in Hepatic IR from baseline to 13 weeks
Description
Graded hyperinsulinemic euglycemic clamp with glucose and glycerol isotopes to assess metformin's impact on: • Hepatic IR
Time Frame
0-13 weeks
Title
Change in Adipose IR from baseline to 13 weeks
Description
Graded hyperinsulinemic euglycemic clamp with glucose and glycerol isotopes to assess metformin's impact on: • Adipose IR
Time Frame
0-13 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. Meets eligibility criteria of the main study, Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (NCT01881828). Exclusion Criteria: 1. Low hemoglobin or hematocrit as defined by each local institution's rules for insulin clamps or if no institutional requirements a Hematocrit <30% or hemoglobin <10 gm/dL
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kellee M Miller, MPH
Organizational Affiliation
Jaeb Center for Health Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ingrid Libman, MD, PhD
Organizational Affiliation
Childrens Hospital of University of Pittsburgh Medical Center
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Kristen Nadeau, MD
Organizational Affiliation
University of Colorado Denver/Childrens Hospital Colorado
Official's Role
Study Chair
Facility Information:
Facility Name
Jaeb Center for Health Research
City
Tampa
State/Province
Florida
ZIP/Postal Code
33647
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
14514603
Citation
Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, Rewers M. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care. 2003 Oct;26(10):2923-8. doi: 10.2337/diacare.26.10.2923.
Results Reference
background
PubMed Identifier
15677783
Citation
Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005 Feb;28(2):301-6. doi: 10.2337/diacare.28.2.301.
Results Reference
background
PubMed Identifier
15855566
Citation
Wadwa RP, Kinney GL, Maahs DM, Snell-Bergeon J, Hokanson JE, Garg SK, Eckel RH, Rewers M. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care. 2005 May;28(5):1051-6. doi: 10.2337/diacare.28.5.1051.
Results Reference
background
PubMed Identifier
3113569
Citation
Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed). 1987 Jun 27;294(6588):1651-4. doi: 10.1136/bmj.294.6588.1651.
Results Reference
background
PubMed Identifier
3825934
Citation
Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987 Apr 1;59(8):750-5. doi: 10.1016/0002-9149(87)91086-1.
Results Reference
background
PubMed Identifier
15467773
Citation
Snell-Bergeon JK, Hokanson JE, Kinney GL, Dabelea D, Ehrlich J, Eckel RH, Ogden L, Rewers M. Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium. Int J Obes Relat Metab Disord. 2004 Dec;28(12):1594-9. doi: 10.1038/sj.ijo.0802796.
Results Reference
background
PubMed Identifier
15699257
Citation
Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005 Feb 15;111(6):747-53. doi: 10.1161/01.CIR.0000155251.03724.A5. Epub 2005 Feb 7.
Results Reference
background
PubMed Identifier
12716791
Citation
Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2003 May;26(5):1374-9. doi: 10.2337/diacare.26.5.1374.
Results Reference
background
PubMed Identifier
15983263
Citation
Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, Skarlatos S, Wassef M, Rabadan-Diehl C; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation. 2005 Jun 28;111(25):3489-93. doi: 10.1161/CIRCULATIONAHA.104.529651. No abstract available.
Results Reference
background
PubMed Identifier
8640398
Citation
Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):720-6. doi: 10.1161/01.atv.16.6.720.
Results Reference
background
PubMed Identifier
14747240
Citation
Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, Fuller JH; EURODIAB Prospective Complications Study Group. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care. 2004 Feb;27(2):530-7. doi: 10.2337/diacare.27.2.530.
Results Reference
background
PubMed Identifier
3523245
Citation
Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986 Jul 24;315(4):215-9. doi: 10.1056/NEJM198607243150402.
Results Reference
background
PubMed Identifier
8487645
Citation
Arslanian S, Heil BV, Kalhan SC. Hepatic insulin action in adolescents with insulin-dependent diabetes mellitus: relationship with long-term glycemic control. Metabolism. 1993 Mar;42(3):283-90. doi: 10.1016/0026-0495(93)90075-y.
Results Reference
background
PubMed Identifier
2404722
Citation
Arslanian S, Nixon PA, Becker D, Drash AL. Impact of physical fitness and glycemic control on in vivo insulin action in adolescents with IDDM. Diabetes Care. 1990 Jan;13(1):9-15. doi: 10.2337/diacare.13.1.9.
Results Reference
background
PubMed Identifier
12702748
Citation
Heptulla RA, Stewart A, Enocksson S, Rife F, Ma TY, Sherwin RS, Tamborlane WV, Caprio S. In situ evidence that peripheral insulin resistance in adolescents with poorly controlled type 1 diabetes is associated with impaired suppression of lipolysis: a microdialysis study. Pediatr Res. 2003 May;53(5):830-5. doi: 10.1203/01.PDR.0000059552.08913.B7.
Results Reference
background
PubMed Identifier
19915016
Citation
Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, Zeitler P, Draznin B, Reusch JE. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab. 2010 Feb;95(2):513-21. doi: 10.1210/jc.2009-1756. Epub 2009 Nov 13.
Results Reference
background
PubMed Identifier
9669786
Citation
Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998 Jul 8;280(2):140-6. doi: 10.1001/jama.280.2.140. Erratum In: JAMA 1998 Nov 4;280(17):1484.
Results Reference
background
PubMed Identifier
15211099
Citation
Regensteiner JG. Type 2 diabetes mellitus and cardiovascular exercise performance. Rev Endocr Metab Disord. 2004 Aug;5(3):269-76. doi: 10.1023/B:REMD.0000032416.13070.01. No abstract available.
Results Reference
background
PubMed Identifier
9655791
Citation
Regensteiner JG, Bauer TA, Reusch JE, Brandenburg SL, Sippel JM, Vogelsong AM, Smith S, Wolfel EE, Eckel RH, Hiatt WR. Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus. J Appl Physiol (1985). 1998 Jul;85(1):310-7. doi: 10.1152/jappl.1998.85.1.310.
Results Reference
background
PubMed Identifier
19346991
Citation
Regensteiner JG, Bauer TA, Reusch JE, Quaife RA, Chen MY, Smith SC, Miller TM, Groves BM, Wolfel EE. Cardiac dysfunction during exercise in uncomplicated type 2 diabetes. Med Sci Sports Exerc. 2009 May;41(5):977-84. doi: 10.1249/MSS.0b013e3181942051.
Results Reference
background
PubMed Identifier
14988302
Citation
Rewers M, Zaccaro D, D'Agostino R, Haffner S, Saad MF, Selby JV, Bergman R, Savage P; Insulin Resistance Atherosclerosis Study Investigators. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004 Mar;27(3):781-7. doi: 10.2337/diacare.27.3.781.
Results Reference
background
PubMed Identifier
10189532
Citation
Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999 Apr;22(4):562-8. doi: 10.2337/diacare.22.4.562.
Results Reference
background
PubMed Identifier
19584191
Citation
Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B, Reusch JE, Regensteiner JG. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab. 2009 Oct;94(10):3687-95. doi: 10.1210/jc.2008-2844. Epub 2009 Jul 7.
Results Reference
background
PubMed Identifier
12933352
Citation
Perseghin G, Lattuada G, Danna M, Sereni LP, Maffi P, De Cobelli F, Battezzati A, Secchi A, Del Maschio A, Luzi L. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab. 2003 Dec;285(6):E1174-81. doi: 10.1152/ajpendo.00279.2003. Epub 2003 Aug 21.
Results Reference
background
PubMed Identifier
11889158
Citation
Greenfield JR, Samaras K, Chisholm DJ. Insulin resistance, intra-abdominal fat, cardiovascular risk factors, and androgens in healthy young women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2002 Mar;87(3):1036-40. doi: 10.1210/jcem.87.3.8324.
Results Reference
background
PubMed Identifier
1526330
Citation
Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes. 1992 Oct;41 Suppl 2:12-7. doi: 10.2337/diab.41.2.s12.
Results Reference
background
PubMed Identifier
2651185
Citation
Nijs HG, Radder JK, Frolich M, Krans HM. The course and determinants of insulin action in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1989 Jan;32(1):20-7. doi: 10.1007/BF00265399.
Results Reference
background
PubMed Identifier
18288188
Citation
Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, Kudlow JE, Michell RH, Olefsky JM, Field SJ, Evans RM. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature. 2008 Feb 21;451(7181):964-9. doi: 10.1038/nature06668.
Results Reference
background
PubMed Identifier
18323454
Citation
Dentin R, Hedrick S, Xie J, Yates J 3rd, Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science. 2008 Mar 7;319(5868):1402-5. doi: 10.1126/science.1151363.
Results Reference
background
PubMed Identifier
2393555
Citation
Koivisto VA, Yki-Jarvinen H. Changes in muscle glucose metabolism in type 1 diabetes. Ann Med. 1990 Jun;22(3):201-5. doi: 10.3109/07853899009147270.
Results Reference
background
PubMed Identifier
18267070
Citation
Chibalin AV, Leng Y, Vieira E, Krook A, Bjornholm M, Long YC, Kotova O, Zhong Z, Sakane F, Steiler T, Nylen C, Wang J, Laakso M, Topham MK, Gilbert M, Wallberg-Henriksson H, Zierath JR. Downregulation of diacylglycerol kinase delta contributes to hyperglycemia-induced insulin resistance. Cell. 2008 Feb 8;132(3):375-86. doi: 10.1016/j.cell.2007.12.035. Erratum In: Cell. 2022 Jan 20;185(2):397-398.
Results Reference
background
PubMed Identifier
2573554
Citation
Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes. 1989 Dec;38(12):1595-601. doi: 10.2337/diab.38.12.1595.
Results Reference
background
PubMed Identifier
18721166
Citation
Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes. 2009 Feb;10(1):5-13. doi: 10.1111/j.1399-5448.2008.00450.x. Epub 2008 Aug 20.
Results Reference
background
PubMed Identifier
12618248
Citation
Moreau KL, Donato AJ, Seals DR, DeSouza CA, Tanaka H. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. Cardiovasc Res. 2003 Mar;57(3):861-8. doi: 10.1016/s0008-6363(02)00777-0.
Results Reference
background
PubMed Identifier
9870469
Citation
Ekstrand AV, Groop PH, Gronhagen-Riska C. Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant. 1998 Dec;13(12):3079-83. doi: 10.1093/ndt/13.12.3079.
Results Reference
background
PubMed Identifier
6754515
Citation
DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1982 Oct;23(4):313-9. doi: 10.1007/BF00253736.
Results Reference
background
PubMed Identifier
17189542
Citation
Van Pelt RE, Gozansky WS, Hickner RC, Schwartz RS, Kohrt WM. Acute modulation of adipose tissue lipolysis by intravenous estrogens. Obesity (Silver Spring). 2006 Dec;14(12):2163-72. doi: 10.1038/oby.2006.253.
Results Reference
background
PubMed Identifier
16291705
Citation
Druet C, Tubiana-Rufi N, Chevenne D, Rigal O, Polak M, Levy-Marchal C. Characterization of insulin secretion and resistance in type 2 diabetes of adolescents. J Clin Endocrinol Metab. 2006 Feb;91(2):401-4. doi: 10.1210/jc.2005-1672. Epub 2005 Nov 15.
Results Reference
background
PubMed Identifier
1443555
Citation
Gilker CD, Pesola GR, Matthews DE. A mass spectrometric method for measuring glycerol levels and enrichments in plasma using 13C and 2H stable isotopic tracers. Anal Biochem. 1992 Aug 15;205(1):172-8. doi: 10.1016/0003-2697(92)90595-x.
Results Reference
background
PubMed Identifier
13833973
Citation
STEELE R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci. 1959 Sep 25;82:420-30. doi: 10.1111/j.1749-6632.1959.tb44923.x. No abstract available.
Results Reference
background
PubMed Identifier
3297886
Citation
Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes. 1987 Aug;36(8):914-24. doi: 10.2337/diab.36.8.914.
Results Reference
background
PubMed Identifier
10454101
Citation
Kamel EG, McNeill G, Han TS, Smith FW, Avenell A, Davidson L, Tothill P. Measurement of abdominal fat by magnetic resonance imaging, dual-energy X-ray absorptiometry and anthropometry in non-obese men and women. Int J Obes Relat Metab Disord. 1999 Jul;23(7):686-92. doi: 10.1038/sj.ijo.0800904.
Results Reference
background
PubMed Identifier
14514347
Citation
Sarnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003 Oct;149(4):323-9. doi: 10.1530/eje.0.1490323.
Results Reference
background
PubMed Identifier
3556289
Citation
Martin FI, Hopper JL. The relationship of acute insulin sensitivity to the progression of vascular disease in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1987 Mar;30(3):149-53. doi: 10.1007/BF00274219.
Results Reference
background
PubMed Identifier
7658949
Citation
Regensteiner JG, Sippel J, McFarling ET, Wolfel EE, Hiatt WR. Effects of non-insulin-dependent diabetes on oxygen consumption during treadmill exercise. Med Sci Sports Exerc. 1995 Jun;27(6):875-81.
Results Reference
background
PubMed Identifier
30938764
Citation
Cree-Green M, Bergman BC, Cengiz E, Fox LA, Hannon TS, Miller K, Nathan B, Pyle L, Kahn D, Tansey M, Tichy E, Tsalikian E, Libman I, Nadeau KJ. Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3265-3278. doi: 10.1210/jc.2019-00129.
Results Reference
derived

Learn more about this trial

Insulin Clamp Ancillary Study for Assessment of Insulin Resistance

We'll reach out to this number within 24 hrs